Custom-Made vaccine takes on ovarian cancer
NCT ID NCT03839524
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial tested a personalized immunotherapy called TG4050 in 64 women with advanced ovarian, fallopian tube, or peritoneal cancer who had completed standard chemotherapy and were in complete remission. The treatment is made from each patient's unique tumor mutations and given as injections to help the immune system recognize and attack any remaining cancer cells. The main goal was to check safety and tolerability, with some early looks at whether it might help prevent recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TG4050 (a personalized cancer vaccine made from the patient's own tumor mutations)
What this could lead to
If successful, this could point toward a new way to keep ovarian cancer from coming back after standard treatment.
What could go wrong
This is an early Phase 1 trial with only 64 participants, so it is mainly checking safety, not yet proven to work. The treatment is personalized and complex, which may limit how widely it can be used.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pitié-Salpêtrière
Paris, 75013, France
-
IUCT Toulouse
Toulouse, 31100, France
-
Institut Curie
Paris, 75005, France
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Phoenix
Phoenix, Arizona, 85259, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States